Literature DB >> 10646046

Effects of racecadotril and loperamide on bacterial proliferation and on the central nervous system of the newborn gnotobiotic piglet.

Y Duval-Iflah1, H Berard, P Baumer, P Guillaume, P Raibaud, Y Joulin, J M Lecomte.   

Abstract

METHODS: The effects of 4 days of oral administration of different doses of two drugs, an enkephalinase inhibitor (the antisecretory agent, racecadotril) and a mu-receptor agonist (loperamide), on intestinal growth of a bacterial nonpathogenic strain (Escherichia coli E 404) and on the central nervous system (CNS) were compared in newborn gnotobiotic piglets.
RESULTS: The E. coli content of the proximal jejunum (segment S1) and the E. coli ratio of stomach:segment S1 were similar in the racecadotril (20 mg/kg b.d., n = 5) and control groups. In contrast, in the loperamide group (1 mg/kg b.d., n = 4), the E. coli content of segment S1 and the E. coli ratio stomach:S1 were both significantly higher than with racecadotril or control (P = 0.04 and 0.005, respectively, for E. coli content; P = 0.05 and 0.03, respectively, for stomach:S1). There were no clinical signs of neurotoxicity and no deaths with racecadotril given orally at a high dose of 130 mg/kg b.d. (n = 5)--nearly 60 times the paediatric dosage. In contrast, an equivalent high dose of loperamide (5 mg/kg b.d.) resulted in death in three out of four piglets.
CONCLUSIONS: In contrast to loperamide, racecadotril did not induce bacterial overgrowth and did not produce central neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10646046     DOI: 10.1046/j.1365-2036.1999.00001.x-i1

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Racecadotril : A Novel Antidiarrheal.

Authors:  N Singh; S Narayan
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

3.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

4.  Opioid Facilitation of β-Adrenergic Blockade: A New Pharmacological Condition?

Authors:  Joseph Vamecq; Karine Mention-Mulliez; Francis Leclerc; Dries Dobbelaere
Journal:  Pharmaceuticals (Basel)       Date:  2015-09-25

Review 5.  A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults.

Authors:  Wolfgang Fischbach; Viola Andresen; Marion Eberlin; Tobias Mueck; Peter Layer
Journal:  Front Med (Lausanne)       Date:  2016-10-14

6.  Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model.

Authors:  Tamlyn Anne Rautenberg; Ute Zerwes; Douglas Foerster; Rick Aultman
Journal:  Clinicoecon Outcomes Res       Date:  2012-04-20

Review 7.  Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials.

Authors:  Marion Eberlin; Min Chen; Tobias Mueck; Jan Däbritz
Journal:  BMC Pediatr       Date:  2018-04-03       Impact factor: 2.125

8.  I, 5. Treatment of viral gastroenteritis.

Authors:  Dorsey Bass
Journal:  Perspect Med Virol       Date:  2004-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.